Introduction The STRIDE consensus suggested to focus on mucosal healing, based on
biomarkers and endoscopy, in addition to clinical endpoints as treatment target. This …

BACKGROUND Remarkable progress over the last decade has equipped clinicians with
many options in the treatment of inflammatory bowel disease. Clinicians now have the …

Ulcerative colitis (UC), an inflammation of the colon lining, represents the main form of
inflammatory bowel disease IBD. Nutritional therapy is extremely important in the …

Background: Treatments for inflammatory bowel diseases (IBD) have evolved in the era of
biologics. However, the real-world data on their usage patterns and sequencing are still …

Abstract Background and Aims Switching from the intravenous to the subcutaneous
biosimilar infliximab (SC-IFX) has been shown to safely maintain clinical remission and …

Background: Only limited information is available on cost efficacy of the advanced therapies
for the treatment of ulcerative rectocolitis. We evaluated the efficacy and the treatment costs …

The prevalence of inflammatory bowel disease (IBD) has been rising significantly in recent
years. It is widely accepted that gut microbes play an essential role in the development of …

Background: Only limited information is available on cost efficacy of the advanced therapies
for the treatment of ulcerative rectocolitis. We evaluated the efficacy and the treatment costs …

In dieser Stellungnahme erfolgt eine Bewertung des möglichen Zusatznutzens von
Risankizumab im Vergleich zur zweckmäßigen Vergleichstherapie bei erwachsenen …

Adalimumab products are tumor necrosis factor inhibitors (TNFis) approved for the following
uses: 1• Ankylosing spondylitis, for reducing signs and symptoms in adults with active …